Syngene International Ltd
SYNGENESyngene International Ltd
SYNGENE
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 72.37 | 8.19 | 0.14% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.09 | 6.40 | 0.53% |
Forecast & Ratings
Detailed Forecast from 7 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.
Investor Presentation
View olderPeers
Compare with peersDivi's Laboratories Ltd
Aarti Pharmalabs Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Brooks Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,484.90 | 1,900.70 | 2,164.80 | 2,283.90 | 2,657.00 | 3,263.80 | 3,579.20 | 3,563.10 | ||||||||
Raw Materials | 395.20 | 505.30 | 518.60 | 551.70 | 770.60 | 902.20 | 873.60 | 2,491.80 | ||||||||
| Power & Fuel Cost | 34.70 | 41.30 | 45.80 | 57.40 | 64.80 | 69.20 | 69.70 | |||||||||
| Employee Cost | 379.60 | 472.70 | 580.40 | 660.20 | 718.10 | 841.70 | 888.70 | |||||||||
| Selling & Administrative Expenses | 116.20 | 123.10 | 123.80 | 107.80 | 137.60 | 196.70 | 249.00 | |||||||||
| Operating & Other expenses | 32.60 | 146.40 | 125.40 | 135.40 | 147.70 | 248.70 | 404.30 | |||||||||
EBITDA | 526.60 | 611.90 | 770.80 | 771.40 | 818.20 | 1,005.30 | 1,093.90 | 1,071.30 | ||||||||
| Depreciation/Amortization | 131.40 | 164.20 | 219.30 | 274.50 | 309.70 | 366.50 | 425.90 | 437.00 | ||||||||
| PBIT | 395.20 | 447.70 | 551.50 | 496.90 | 508.50 | 638.80 | 668.00 | 634.30 | ||||||||
| Interest & Other Items | 22.70 | 32.30 | 34.60 | 27.70 | 24.10 | 45.20 | 47.20 | 48.50 | ||||||||
| PBT | 372.50 | 415.40 | 516.90 | 469.20 | 484.40 | 593.60 | 620.80 | 585.80 | ||||||||
| Taxes & Other Items | 67.10 | 83.80 | 104.80 | 64.30 | 88.60 | 129.20 | 110.80 | 103.90 | ||||||||
| Net Income | 305.40 | 331.60 | 412.10 | 404.90 | 395.80 | 464.40 | 510.00 | 481.90 | ||||||||
| EPS | 7.63 | 8.29 | 10.30 | 10.12 | 9.89 | 11.58 | 12.70 | 11.99 | ||||||||
| DPS | 0.50 | 0.25 | 0.00 | 0.00 | 1.00 | 1.25 | 1.25 | 1.25 | ||||||||
| Payout ratio | 0.07 | 0.03 | 0.00 | 0.00 | 0.10 | 0.11 | 0.10 | 0.10 |
Company Updates
Peers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Syngene International Ltd | 68.38 | 8.19 | 0.14% |
| Divi's Laboratories Ltd | 99.52 | 11.73 | 0.50% |
| Aarti Pharmalabs Ltd | 27.30 | 3.37 | 0.46% |
| Dishman Carbogen Amcis Ltd | -23.34 | 0.64 | — |
Price Comparison
Compare SYNGENE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Syngene International Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
ICICI Prudential ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8387% | Percentage of the fund’s portfolio invested in the stock 2.04% | Change in the portfolio weight of the stock over the last 3 months 0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/88 (+1) |
ICICI Prudential Large & Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6793% | Percentage of the fund’s portfolio invested in the stock 1.38% | Change in the portfolio weight of the stock over the last 3 months -0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 65/119 (-4) |
Nippon India Focused Equity Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6571% | Percentage of the fund’s portfolio invested in the stock 2.70% | Change in the portfolio weight of the stock over the last 3 months 0.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/36 (+3) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Syngene International Ltd
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 28, 2024
Dividend/Share
₹1.25
Ex DateEx Date
Jun 28, 2024
Cash Dividend
Ex DateEx DateJun 30, 2023
Dividend/Share
₹0.75
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJun 30, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Net profit of Syngene International declined 8.93% to Rs 106.10 crore in the quarter ended September 2024 as against Rs 116.50 crore during the previous quarter ended September 2023. Sales declined 2.10% to Rs 891.00 crore in the quarter ended September 2024 as against Rs 910.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales891.00910.10 -2 OPM %27.4727.92 - PBDT248.20262.70 -6 PBT137.30158.10 -13 NP106.10116.50 -9 Powered by Capital Market - Live
The Board of Syngene International at its meeting held on 23 October 2024 has approved the following change in management: Resignation of Sibaji Biswas, Executive Director and Chief Financial Officer (Key Managerial Personnel) from the services of the Company with effect from 30 November 2024. Appointment of Deepak Jain as the Chief Financial Officer and a Key Managerial Personnel of the Company effective from 01 December 2024. Appointment of Dr. Jayashree Aiyar as Chief Scientific Officer and a member of the Executive Committee (Senior Management Personnel) of the Company effective from 23 October 2024.Powered by Capital Market - Live
Syngene International will hold a meeting of the Board of Directors of the Company on 23 October 2024Powered by Capital Market - Live
Syngene International and 4 other stocks close below VWAP
Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient
Syngene Q1 Results: Net profit down 19% to ₹75.7 crore
Syngene Q1 Results: Net profit drops 19% to Rs 76 crore
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.49%, vs industry avg of 4.51%
Increasing Market Share
Over the last 5 years, market share increased from 15.5% to 20.32%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 8.99%, vs industry avg of 5.9%